Comparison of fully-automated radiosyntheses of [11C]erlotinib for preclinical and clinical use starting from in target produced [11C]CO2 or [11C]CH4

Comparison of fully-automated radiosyntheses of [11C]erlotinib for preclinical and clinical use starting from in target produced [11C]CO2 or [11C]CH4

Abstract Background [11C]erlotinib has been proposed as a PET tracer to visualize the mutational status of the epidermal growth factor receptor (EGFR) in cancer patients. For clinical use, a stable, reproducible and high-yielding radiosynthesis method is a prerequisite. In this work, two production...

Full description

Bibliographic Details
Main Authors: Cécile Philippe, Severin Mairinger, Verena Pichler, Johann Stanek, Lukas Nics, Markus Mitterhauser, Marcus Hacker, Thomas Wanek, Oliver Langer, Wolfgang Wadsak
Format: Article
Language:English
Published: SpringerOpen 2018-05-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
[11C]erlotinib
Radiosynthesis
PET
EGFR
Tyrosine kinase inhibitor
HPLC
Online Access:http://link.springer.com/article/10.1186/s41181-018-0044-1

Internet

http://link.springer.com/article/10.1186/s41181-018-0044-1

Similar Items